What question did this study set out to answer?

Investigate the prevalence of BRAF, KRAS, NRAS, and MEK1 mutations in lung cancers resistant to EGFR TKIs.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

View Full Paper

Ask AI

Bookmark

Investigate the prevalence of BRAF, KRAS, NRAS, and MEK1 mutations in lung cancers resistant to EGFR TKIs.
Analyzed mutations in 212 lung cancer samples for resistance against EGFR TKIs.
Modeling was performed using EGFR-mutant human tumor cell lines.
Assessed sensitivity to concurrent EGFR and MEK inhibition in resistant cell lines.
Found BRAF mutations in 2 of 195 samples (1%), including G469A and V600E.
No recurrent mutations in KRAS, NRAS, or MEK1 were detected among the analyzed samples.
Ectopic expression of mutant NRAS or BRAF conferred resistance to EGFR TKIs, which could be overcome by a MEK inhibitor.

No takes yet. Share an insight, caveat, or question.

Randomized trial shows BRAF mutations in lung cancers with acquired resistance to EGFR inhibitors, suggesting unique resistance mechanisms.

Ohashi et al. (2012) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows BRAF mutations in lung cancers with acquired resistance to EGFR inhibitors, suggesting unique resistance mechanisms.